The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model - Gaspari, Tracey; Welungoda, Iresha; Widdop, Robert E; Simpson, Richard W; Dear, Anthony E (Diabetes & vascular disease research, 2013)
Keywords: Animals; Apolipoproteins E - deficiency; Apolipoproteins E - metabolism; Atherosclerosis - diagnosis; Atherosclerosis - drug therapy; Diabetes Mellitus, Type 2 - drug therapy; Disease Models, Animal; Disease Progression; Endothelial Cells - drug effects; Glucagon-Like Peptide 1 - analogs & derivatives; Glucagon-Like Peptide 1 - therapeutic use; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents - therapeutic use; Liraglutide; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic - diagnosis; Plaque, Atherosclerotic - drug therapy; Receptors, Glucagon - agonists; liraglutide; atherosclerosis; Incretin; endothelial dysfunction; glucagon-like peptide-1; plaque stability